PMN update- 2020 in reviewhttps://promisneurosciences.com/news/year-in-review-looking-forward-to-2021/
Here is the 2020 review from PMN's Dr. Goldstein. It provides a good overview on the status of current programs. It also has some new analysis on aducanumab, still leaning towards approval.
It mentions external challenges with regard to PMN310 capital raise. Not having any optics on who they are targeting, it is hard for me to assess the validity of these statements. Obviously COVID has been disruptive with regard to prioritization in pharma. Maybe some of the companies with large COVID revenues and lots of cash already on hand (i.e. Pfizer) would be a good target.
They have mentioned that $10M is the ask for PHI support. But it is worth contemplating that PHII and PHIII are likely much more costly, so at the end of the day, it's not just an ask for $10M (from a corporate partner/investor planning perspective).